Market Overview

Needham Incrementally Bullish On Cara Therapeutics After CR845 Meets Endpoints

Share:
Needham Incrementally Bullish On Cara Therapeutics After CR845 Meets Endpoints

Cara Therapeutics Inc (NASDAQ: CARA) stock spiked 34 percent Wednesday after the company reported that a Phase 2/3 trial for intravenous CR845 met primary and secondary endpoints.

The investor bullishness resonated with Needham. 

The Rating

Needham analyst Alan Carr maintained a Buy rating on Cara and raised the price target from $23 to $28.

The Thesis

Although Cara’s high dose met primary endpoints for pain relief, the low dose missed statistical significance. Nonetheless, the analyst regards the profile of the post-surgery pain reliever, including low addictive qualities and low rates of nausea and vomiting, as “attractive.” (See Carr's track record here.) 

Carr expects Cara will need to complete another Phase 3 trial in post-surgical pain before securing regulatory approval for the candidate, but the positive Phase 2/3 results are seen to reduce program risk.

Needham predicts the follow-up trial will begin in early 2019 with commercial launch in the second half of 2021. It also anticipates Phase 3 trial results for intravenous CR845 in uremic pruritus — an indication seen to be Cara’s strategic priority — in the first half of 2019.

Price Action

Cara shares were trading up 1 percent at $18.24 at the time of publication Thursday morning. 

Related Links:

Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment

Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Latest Ratings for CARA

DateFirmActionFromTo
Jul 2019MaintainsOverweight
May 2019MaintainsBuy
May 2019MaintainsBuy

View More Analyst Ratings for CARA
View the Latest Analyst Ratings

Posted-In: Alan Carr Joseph StringerAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (CARA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NCMIBenchmarkMaintains12.0
FWONAFBN SecuritiesDowngrades
BXCitiDowngrades52.0
TRVBank of AmericaDowngrades
PSTGCross ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Vanguard Plans To Flex Low-Cost Muscle In The ESG ETF Space

Imperial Capital Takes Neutral Stance On Disney, Tackles Pros, Cons Of A Twenty-First Century Fox Deal